These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 23231016)

  • 1. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
    Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J
    Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States.
    Thornburg CD; Carpenter S; Zappa S; Munn J; Leissinger C
    Haemophilia; 2012 Jul; 18(4):568-74. PubMed ID: 22335526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis in adults with haemophilia.
    Hay CR
    Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
    Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
    Manco-Johnson M
    Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
    Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
    Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prophylaxis in an adult patient with severe haemophilia A. Factor VIII consumption and effectiveness.
    Schlenkrich S; Schubert C
    Hamostaseologie; 2013 Aug; 33(3):241-4. PubMed ID: 23435748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of arthropathy in haemophilia: prophylaxis.
    Santagostino E; Mancuso ME
    Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates.
    Nijdam A; Foppen W; De Kleijn P; Mauser-Bunschoten EP; Roosendaal G; van Galen KP; Schutgens RE; van der Schouw YT; Fischer K
    Thromb Haemost; 2016 May; 115(5):931-8. PubMed ID: 26791021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M; Williams M; Chalmers E; Liesner R; Collins P; Vidler V; Hanley J;
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis therapy in haemophilia A: current situation in Spain.
    Lucía JF; Aznar JA; Abad-Franch L; Escuin RR; Jiménez-Yuste V; Pérez R; Batlle J; Balda I; Alperovich G; Parra R;
    Haemophilia; 2011 Jan; 17(1):75-80. PubMed ID: 21070481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
    Mancuso ME; Graca L; Auerswald G; Santagostino E
    Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
    Lindvall K; Astermark J; Björkman S; Ljung R; Carlsson KS; Persson S; Berntorp E
    Haemophilia; 2012 Nov; 18(6):855-9. PubMed ID: 22681244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
    Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS
    Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
    Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
    Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.